A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP

Clinical trial NCT03102593 · COMPLETED

Trial details

NCT number: NCT03102593
Sponsor: argenx
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Primary Immune Thrombocytopenia

Start date: 2017-03-13
Primary completion: 2019-04-09
Enrollment: 38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.